TL;DR
Noom has announced a new GLP-1Rx program offering prescription weight loss medications like Ozempic, integrated with behavioral support. The program aims to provide personalized treatment at accessible prices for qualifying users. Details on eligibility and medication access are still emerging.
Noom has introduced a new GLP-1 medication program, called GLP-1Rx, which combines doctor-prescribed weight-loss drugs with its established behavioral support system. This development marks a significant expansion of Noom’s health offerings, aiming to provide accessible, personalized weight management solutions.
According to Noom, the GLP-1Rx program includes access to medications such as Ozempic® and Zepbound®, starting at $99 for users who meet clinical criteria. The program is developed by medical professionals and backed by Noom’s behavioral change model, emphasizing sustainable habits alongside medication use.
Participants will undergo a quiz to assess eligibility, connect with licensed clinicians, and, if approved, begin a customized treatment plan. The program also offers ongoing medication management and support through Noom’s GLP-1 Companion, a digital tool providing resources on side effects, nutrition, and movement. Access to the medication and support services is designed to be comprehensive and personalized.
While the medication options are brand-name drugs, costs depend on insurance coverage, with out-of-pocket expenses starting at $69 plus medication costs. The program aims to make GLP-1 therapies more accessible, addressing the high demand and interest in these drugs for weight loss.
Implications for Weight Loss Accessibility and Support
This launch is significant because it integrates prescription weight-loss medications with behavioral health support, potentially improving long-term outcomes. By offering medications like Ozempic at accessible prices and combining them with psychological tools, Noom aims to enhance adherence and effectiveness. This approach could influence how weight management programs are delivered, emphasizing personalized, medically supervised treatment alongside behavioral change.
For consumers, this means a more integrated, supportive pathway to weight loss that addresses both biological and psychological factors. It also reflects the growing mainstream acceptance of GLP-1 drugs as a weight management tool, beyond their original use for diabetes.
Ozempic weight loss medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Expansion of GLP-1 Use in Weight Management
GLP-1 receptor agonists like Ozempic and Zepbound have gained popularity for their effectiveness in weight loss, driven by high-profile media coverage and clinical studies. These drugs, initially approved for type 2 diabetes, have shown significant promise for weight reduction in non-diabetic populations.
Several health providers and insurers have begun incorporating GLP-1 therapies into weight management programs, but access has often been limited by cost and availability. Noom’s new program aims to bridge this gap by offering prescription medications within its behavioral support framework, making these drugs more accessible to a broader audience.
This development follows a trend of mainstream health companies integrating pharmacotherapy with digital health tools, seeking to improve outcomes and patient engagement in weight loss efforts.
“Noom’s integration of prescription medications with behavioral support aims to provide a more comprehensive approach to weight management.”
— an anonymous researcher
GLP-1 receptor agonist drugs
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Unclear Details on Eligibility and Coverage
It is not yet clear how widely the program will be available, what the specific eligibility criteria are beyond the initial quiz, or how insurance coverage will impact costs for different users. The full list of participating medications and their pricing structures are still being clarified.
Additionally, long-term outcomes and safety data for combining Noom’s behavioral support with GLP-1 medications are still emerging, and further research may influence program adjustments.
behavioral support weight management
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Next Steps for Program Rollout and User Access
Noom plans to expand its GLP-1Rx program nationally, with updates on eligibility criteria and medication options expected in the coming months. Users interested in participating should monitor Noom’s official channels for announcements. Clinicians and healthcare providers will likely receive guidance on integrating this program into their practices, and further data on effectiveness will be published as the program progresses.
prescription weight loss drugs
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Who is eligible to join Noom’s GLP-1Rx program?
Eligibility is determined through a quiz and clinical assessment; only those who meet specific health criteria can access prescription medications through the program.
What medications are offered in the program?
The program includes brand-name GLP-1 drugs like Ozempic® and Zepbound®, with availability depending on clinical approval.
How much does the program cost?
Access to medications starts at $99 for qualifying users, with additional out-of-pocket costs depending on insurance coverage and medication prices.
Can anyone access these medications through Noom?
No, access is limited to users who meet clinical eligibility criteria after assessment.
What support does Noom provide alongside medication?
Participants receive ongoing support via the GLP-1 Companion app, including resources on side effects, nutrition, movement, and personalized coaching.
Source: Greatist
